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OBJECTIVES This study was performed to evaluate the characteristics, mode of inheritance and etiology of
familial dilated cardiomyopathy (FDC).
BACKGROUND A genetic form of disease transmission has been identified in a relevant proportion of patients
with dilated cardiomyopathy (DCM). Variable clinical characteristics and patterns of
inheritance, and an increased frequency of cardiac antibodies have been reported. An analysis
of FDC may improve the understanding of the disease and the management of patients.
METHODS Of 350 consecutive patients with idiopathic DCM, 281 relatives from 60 families were
examined. Family studies included clinical examination, electrocardiography, echocardiogra-
phy and blood sampling. Of the 60 DCM index patients examined, 39 were attributable to
FDC and 21 were due to sporadic DCM. Clinical features, histology, mode of inheritance
and autoimmune serology were examined, molecular genetic studies were undertaken and the
difference between familial and sporadic forms was analyzed.
RESULTS Only a younger age (p 5 0.0005) and a higher ejection fraction (p 5 0.03) could clinically
distinguish FDC patients from those with sporadic DCM. However, a number of distinct
subtypes of FDC were identified: 1) autosomal dominant, the most frequent form (56%); 2)
autosomal recessive (16%), characterized by worse prognosis; 3) X-linked FDC (10%), with
different mutations of the dystrophin gene; 4) a novel form of autosomal dominant DCM
with subclinical skeletal muscle disease (7.7%); 5) FDC with conduction defects (2.6%), and
6) rare unclassifiable forms (7.7%). The forms with skeletal muscle involvement were
characterized by a restrictive filling pattern; the forms with isolated cardiomyopathy had an
increased frequency of organ-specific cardiac autoantibodies. Histologic signs of myocarditis
were frequent and nonspecific.
CONCLUSIONS Familial dilated cardiomyopathy is frequent, cannot be predicted on a clinical or morphologic
basis and requires family screening for identification. The phenotypic heterogeneity, different
patterns of transmission, different frequencies of cardiac autoantibodies and the initial
molecular genetic data indicate that multiple genes and pathogenetic mechanisms can lead to
FDC. (J Am Coll Cardiol 1999;34:181–90) © 1999 by the American College of Cardiology
Dilated cardiomyopathy (DCM) is a disease of the myocar-
dium associated with dilation and impaired contraction of
the left or both ventricles (1). Dilated cardiomyopathy
represents a major cause of morbidity and mortality among
cardiovascular diseases, and is a leading indication for heart
transplantation. Viral persistence, the presence of an auto-
immune response against myocardial epitopes and genetic
factors are believed to play a major pathogenic role (1).
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Familial dilated cardiomyopathy (FDC) was very rarely
reported in the past (2). Nevertheless, studies based on a
more careful evaluation of disease inheritance (3,4) and,
more recently, on a prospective systematic family screening,
revealed a high frequency of genetic transmission of the
disease, ranging from 20% to 35% in different populations
(5–7). However, the true frequency is probably still under-
estimated due to the absence of early markers of the disease
and reduced penetrance. Furthermore, affected individuals
can be missed in small families and there is an absence of
reliable markers to discriminate between the familial and the
sporadic forms of DCM (5–7).
The occurrence of genetic transmission indicates the
existence of a defective gene (or genes). Familial dilated
cardiomyopathy is probably a complex trait with a major
gene causing the disease and other factors altering its
expressivity, such as modifier genes and environmental
factors. Among potential modifier genes (or susceptibility
factors), an abnormal immune response has long been
suspected. Circulating cardiac-specific autoantibodies were
detected in 20% of first-degree relatives of DCM patients
and in 58% of the pedigrees studied, including both FDC
and sporadic cases (8).
To understand the phenotype and the molecular basis of
FDC, a prospective survey was undertaken in 1991 in a
series of 350 consecutive patients diagnosed with DCM. In
particular, the purpose of this study was to investigate the
clinical and instrumental features of the disease, the modes
of inheritance, the characteristics of the immune response
and the differences between the sporadic and familial forms
to establish a basis for the detection of the specific genetic
defects.
METHODS
Patient population. From 1991 to July 1997, 511 patients
with primary cardiomyopathies were studied in our Institu-
tion, as approved by the institutional review committee and
after obtaining informed consent. Of them, 350 (68%) were
classified as idiopathic DCM. All DCM patients were
evaluated by clinical examination, electrocardiography
(standard electrocardiography, Holter monitoring and
signal-averaged electrocardiography) and echocardiography
(M mode, cross-sectional and Doppler). The data were
interpreted by two independent observers. Normal values
for echocardiographic measurements were determined ac-
cording to standard protocols (9). Additional investigations
routinely performed on index patients included standard
laboratory examinations (including serum creatine kinase
[CK]), chest X ray, exercise test, radionuclide angiography
and an extensive invasive evaluation, including ventriculog-
raphy, coronary angiography and endomyocardial biopsy.
The assessment of DCM was based on strict diagnostic
criteria (1,10) requiring the presence of depressed left
ventricular systolic function (fractional shortening ,25%
and/or ejection fraction ,45%), associated with left ven-
tricular dilation (left ventricular end-diastolic diameter
.117% of the predicted value corrected for the age and
body surface area [11]), in the absence of any known cause
of heart disease. Exclusion criteria were: moderate to severe
arterial hypertension, coronary artery disease, arrhythmo-
genic right ventricular dysplasia, excessive alcohol consump-
tion, high rate supraventricular arrhythmia, significant val-
vular heart disease, systemic diseases, pericardial diseases,
congenital heart disease and cor pulmonale. Histologic signs
of myocarditis were not considered exclusion criteria.
Family studies. For each DCM index patient, a detailed
two- to six-generation pedigree was constructed. Since the
aim of this study was an extensive analysis of the phenotype
and molecular basis of FDC, the selection of the families
was based on their availability for family screening. A
noninvasive familial screening was offered, regardless of
family history, and then performed in all available relatives
by means of clinical examination, electrocardiography,
echocardiography and, in selected cases, signal-averaged
electrocardiography. Relatives showing signs of myocardial
disease underwent full invasive evaluation as described for
the index patients (see preceding section), with the exclu-
sion of six subjects under 20 years of age and seven adults
unable to undergo invasive studies. In these cases, noninva-
sive investigation (10,12) and a review of previous hospital
records completed the evaluation. For the deceased relatives,
hospital records were examined when available, family
physicians were interviewed and multiple informants among
close relatives were consulted for accuracy of diagnosis.
Criterion for the diagnosis of FDC was the presence of at
least two family members with documented DCM. After
the identification of genetic transmission, family members
were invited to participate in a follow-up program with
periodic examinations to evaluate the evolution of the
clinical status in both affected and unaffected individuals and
to avoid the risk of misdiagnosis. Two hundred clinical and
instrumental parameters were recorded in a database for
statistical analysis.
Histologic studies. Endomyocardial biopsy from the right
or the left ventricle was performed in 83 affected individuals
during diagnostic heart catheterization. The number of
biopsies ranged from four to five specimens in each patient.
The biopsies were processed and analyzed as reported in
detail elsewhere (13). Active myocarditis was assessed ac-
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182 Mestroni et al. JACC Vol. 34, No. 1, 1999
Heterogeneity of Familial DCM July 1999:181–90
cording to the Dallas criteria (14). Morphometric analysis
was performed in 44 cases and assessed as previously
described (13), with at least three samples from each patient
being examined to obtain a mean value for each parameter.
To examine skeletal muscle for the presence of pathologic
changes, a needle biopsy of the quadriceps was obtained
from 14 patients available for this study, after informed
consent. Signs of skeletal myopathy or an abnormal serum
CK were not required. The tissue samples were prepared
and stained according to standard histologic procedures.
Immunohistochemical studies on endomyocardial and skel-
etal muscle samples were performed as previously described
(15).
Genetic, immunologic and immunogenetic studies.
Once the diagnosis was established, blood, sera, deoxyribo-
nucleic acid and lymphoblastoid cell lines (deriving from
immortalization of B lymphocytes with Epstein-Barr virus)
were collected and stored. Samples were obtained from all
index patients and from each available family member.
Methods for gene mapping were based on the analysis of
microsatellite polymorphic markers and linkage analysis as
described in detail elsewhere (16). Methods for the detec-
tion of mutations in the dystrophin gene were based on
multiplex polymerase chain reaction, single-strand confor-
mation polymorphism, restriction enzyme analysis and se-
quence analysis, as previously reported (17). Serum samples
of 73 relatives (affected and unaffected) from families with
FDC were tested for the presence of organ-specific cardiac
autoantibodies using standard indirect immunofluorescence,
as described (8,18). Human leukocyte antigen (HLA) typ-
ing was performed in 51 subjects (affected and unaffected
relatives from families with FDC) on peripheral blood
lymphocytes isolated from heparinized whole blood by
separation on histopaque ficoll density gradient. HLA-DR
typing was performed with the standard lymphocytotoxicity
assay.
Statistical analysis. The method for the identification of
differences between the familial and the sporadic forms of
DCM, and among the different subtypes of FDC, was based
on the uni- and multivariate analysis of 200 clinical,
instrumental and morphologic parameters. Mean and me-
dian values or percentages, where appropriate, were calcu-
lated for all clinical and instrumental variables. The Uni-
variate Odds Ratio was computed via a logit model. The test
for significance of the difference in the mean values among
the groups was based on the Wilcoxon test. For the
categorical variables, the chi-square test (continuity-
adjusted if appropriate) was computed. Multivariate analysis
performed to develop a predictive model was based on all
variables that were shown to be significant in the univariate
analysis at a threshold of 0.25 (19). Variables were selected
for the resulting logit model using a stepwise selection
procedure, based on the Akaike Information Criterion using
a threshold of 0.05. In this study, the criteria for the family
selection were not designed for an estimation of the preva-
lence of FDC.
RESULTS
Family studies. Sixty families of DCM patients were
extensively investigated irrespective of family history. An
overall number of 281 family members underwent family
screening (Table 1). Relatives were assessed as affected when
they met the full criteria for DCM, as unaffected when they
had a normal heart or other causes of heart disease, or as
unknown in cases with minor cardiac abnormalities. Ac-
cording to these criteria, 96 of the relatives were affected,
144 were unaffected and 15 were considered as unknown.
The clinical features of the relatives with unknown status
were the following: left ventricular dilation (eight cases), left
bundle branch block (four), arterial hypertension (six),
complex ventricular arrhythmia (two), segmental hypokine-
sia (one) and skeletal myopathy (three). Twenty-six spouses
of affected family members were studied for the analysis of
the genetic transmission of the disease, but not included in
the statistical analysis of the phenotype.
As defined, FDC was present in 39 families, whereas in
21 families the condition was confirmed to be sporadic. At
the time of the initial evaluation, familial transmission of
the disease had not been identified in three out of 24 cases
with no family history, leading to a misclassification error of
12.5% due to the absence of clinical family screening data.
Analysis of the differences between FDC and sporadic
DCM. In the comparison between FDC and sporadic
DCM only the probands were considered (39 and 21,
respectively) to avoid ascertainment bias, that is, early
disease identified by family screening. Of the 200 parame-
ters analyzed, only three showed a significant difference
between the two groups (Table 2); FDC patients were
characterized by an increased myocardial fibrosis using the
morphometric analysis, a younger age and a trend toward a
higher left ventricular ejection fraction compared with
Table 1. Study Population
Patients with dilated cardiomyopathy (n) 350
Families clinically investigated (n) 60
Subjects examined (n) 281
Affected (n) 96
Unaffected (n) 170
Unknown status (n) 15
Families with familial dilated cardiomyopathy (n) 39
Families with sporadic dilated cardiomyopathy (n) 21
Relatives studied in familial dilated cardiomyopathy (%)
I degree 20
II degree 30
III degree 50
Relatives studied in sporadic dilated cardiomyopathy (%)
I degree 77
II degree 19
III degree 4
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sporadic DCM. However, only the last two parameters were
independent in the multivariate analysis. Moreover, no
significant differences were found between the healthy
relatives of patients with FDC (96 subjects) and those with
sporadic DCM (48 subjects). In this analysis, 15 members
of FDC families with unknown status were not included.
Characterization and classification of FDC. The analysis
of the familial forms revealed broad genetic heterogeneity,
based on different clinical features, different patterns of
genetic transmission and, when available, molecular genetic
data. The classification and the features of the FDC types
are described in detail in Table 3, an example of pedigree for
each subtype of FDC is illustrated in Figure 1 and an
outline of the most important characteristics of each group
is given below.
1. Autosomal dominant (AD) pure FDC was identified in
the majority of families (56%). This form was character-
ized by variable and age-related penetrance (,20 years:
10%, 20 to 30: 34%; 30 to 40: 60%; .40: 90%), with
onset generally in the fourth decade of life. The clinical
and histologic examinations of skeletal muscle appeared
to be normal. Mildly dilated forms (20,21) were frequent
(42%), as were segmental wall motion abnormalities in
the early phases of the disease. In one case, an idiopathic
left ventricular aneurysm was observed (22). In another
family, evidence of histologic myocarditis was found in
one affected individual (Fig. 2). Organ-specific cardiac
autoantibodies were very frequent in this group (39% of
cases were positives), in both affected (72%) and unaf-
fected (27%) family members. In one large family (Fig. 1,
AD-FDC1) and in two other small families, the disease
locus was mapped to chromosome 9 (16).
2. Autosomal recessive (AR) FDC was present in 16% of
our families (Fig. 1, AR-FDC3). The patient age was
significantly younger compared with the AD form (p 5
0.05) and the course of the disease showed a rapid
progression to death or transplant, in less than one year
in 50% of cases, all of which were under 21 years of age
(p , 0.05). Two patients belonging to two different
families showed evidence of myocarditis.
3. Autosomal dominant conduction disease with DCM was
rare in our patient population (Fig. 1, family CDDC1).
Typically, as described by Graber et al. (23), in the two
affected family members the onset of the disease was
characterized by atrioventricular blocks (second and third
degree) and intraventricular conduction delays (left bun-
dle branch block) requiring a permanent pacing, and
supraventricular (atrial flutter) as well as ventricular
arrhythmia. In the early phase of disease, the patients
showed only mild ventricular dysfunction. However,
progressive worsening of heart failure rapidly followed,
requiring heart transplantation in one case.
4. Four families (10%) were included in the group with
X-linked DCM (Table 3, XLDC). They were charac-
terized by X-linked inheritance with no male to male
transmission. In the affected subjects (all male), the onset
appeared later than previously described, with symptoms
of severe progressive heart failure, typically in the absence
of overt clinical signs of skeletal myopathy. Mildly
dilated forms were also observed in these patients. While
a characteristic increase of CK (isoform MM) levels was
observed in this form of the disease, CK levels were
found to be normal in one case. All but one of the
obligate carriers were normal (Fig. 1). A mutation of the
dystrophin gene was demonstrated in the three families
available for molecular diagnosis. In the first family, a
point mutation at the 59 end of the dystrophin gene was
found, consisting of a G to T transversion that altered
the consensus sequence (AG) at the first muscle exon–
intron junction (17). In the second family (Fig. 1, family
XLDC2), multiplex polymerase chain reaction analysis
showed a deletion occurring in exon 48–49 (24). In the
third family, a deletion of the muscle-promoter region
and the first muscle exon had been previously identified
(25). Even in the absence of muscle weakness, skeletal
muscle biopsies showed myopathic changes, such as
variability in fiber size, rare splitting and an increase in
the number of internal nuclei. The endomyocardial
biopsy was characterized by fibrosis and, accordingly,
morphometric analysis showed a trend toward an in-
creased collagen volume fraction and reduced myocyte,
nuclear and myofibrillar areas (Table 3). Immunocyto-
chemical studies with antidystrophin antibodies were
diagnostic, showing that in the skeletal muscle the
protein was reduced in quantity, even if normally local-
ized, whereas dystrophin was undetectable in the cardiac
muscle (17,24,26).
5. The fifth subtype was AD DCM with subclinical skeletal
muscle disease. Of FDC subjects, 7.7% presented a
marked variability of expression (Table 3, MDDC). The
phenotype was characterized by no clinical difference
between affected female and male subjects, variable
degree of skeletal muscle involvement, presence of con-
duction defects, frequent ventricular arrhythmia and
variable levels of the serum CK-MM, from overtly
abnormal to normal values even in the same subjects, at
different stages of the disease. In two of the seven affected,
Table 2. Analysis of the Difference Between Sporadic and
Familial Dilated Cardiomyopathy at Uni- and
Multivariate Analysis
Sporadic DCM
(21 Cases)
FDC
(39 Cases) p
Collagen volume
fraction (%)
21.5 (10.5–28) 37 (20.2–45.7) 0.039
Age (yr) 52 (46–55) 37 (26–45) 0.0005*
LVEF (%) 27 (19–32) 30 (24–39) 0.0306*
*p values at multivariate analysis. Data are expressed as median (first and third
quartile).
DCM 5 dilated cardiomyopathy; FDC 5 familial dilated cardiomyopathy;
LVEF 5 left ventricular ejection fraction.
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the rapid and progressive worsening of heart failure led to
death within 1 year from the diagnosis. Mildly dilated
forms and segmental hypokinesia were observed in this
group. Histologic signs of myocarditis were found in two
cases (Fig. 1, MDDC1 family). The skeletal muscle biopsy
showed dystrophic changes. As expected, dystrophin was
normal in all.
6. Unclassifiable FDC was a heterogeneous group includ-
ing three families (7.7 %) with peculiar phenotypes. The
first group included two families characterized by hypo-
kinetic left ventricle with localized apical hypertrophy of
the left or both ventricles (Fig. 1, AD-HDC1 family,
and Fig. 3), named AD DCM with hypertrophy (Table
3). Histologic signs of myocarditis were also observed in
this group. Autosomal recessive transmission, retinitis
pigmentosa and deafness characterized the second type
(Fig. 1, AR-RPDC1 family). The patients presented a
stable course of the disease after a follow-up to 7.5 years.
The left ventricle was only mildly dilated. Serum CK,
lactate and karyotype were normal; mitochondrial de-
oxyribonucleic acid analysis revealed absence of mac-
rodeletions and of the most common point mutations.
Search for predictive parameters within the familial
forms. To identify specific features, and to have a statisti-
cally representative sample, the different forms of FDC were
clustered into two groups: patients with isolated myocardial
disease (including 63 affected members of 28 families with
AD or AR FDC) and patients with skeletal muscle involve-
ment (including 11 affected members of seven families with
X-linked dilated cardiomyopathy [XLDC] and AD dilated
cardiomyopathy with subclinical muscle involvement
[MDDC]). Families with unclassifiable forms were not
included in this analysis. The results of the uni- and
multivariate analysis are reported in Table 4. Familial
dilated cardiomyopathy forms with skeletal muscle involve-
ment were characterized by clinical and echocardiographic
restrictive filling patterns and by a significant increase of
Figure 1. Pedigrees of families with different forms of familial dilated cardiomyopathy (FDC). 1. AD-FDC1: the key members of this
family after the last follow-up screening (1997), consistent with autosomal dominant inheritance (male to male transmission) and
age-related penetrance (almost complete absence of affected in the last generation). 2. AR-FDC3: autosomal recessive FDC, in which the
affected were respectively 12 and 16 years old at diagnosis. 3. XLDC2: FDC with X-linked transmission, in this family due to a deletion
of exons 48–49 (24). 4. MDDC1: autosomal dominant transmission and subclinical skeletal muscle involvement. 5. AD-HDC1: a form
of unclassifiable FDC with autosomal dominant transmission and a phenotype characterized by mild dilation, systolic dysfunction and
apical hypertrophy. 6. AR-RPDC1: another unclassifiable FDC with autosomal recessive transmission associated with retinitis pigmentosa
and hearing loss. Finally, CDDC1: autosomal dominant family with conduction defects and subsequent development of severe ventricular
dilation and dysfunction. Individuals are indicated by generation and pedigree number. Affected status is indicated by filled symbols,
unaffected status by clear symbols and unknown status (individuals with equivocal or suspected dilated cardiomyopathy) by gray symbols.
The probands are indicated by arrows.
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serum CK-MM. On the other hand, pure FDC was
characterized by the presence of cardiac autoantibodies,
which was the only independent predictor. Human leuko-
cyte DR4 antigen did not correlate with the presence of
autoantibodies in these patients, and was not associated
with the disease status in the overall FDC population.
In the familial forms, the affected status was significantly
associated with the male gender (2:1 vs. 1:1, p 5 0.046),
also after exclusion of XLDC, and with the presence of
organ-specific cardiac autoantibodies (16% vs. 2%, p 5
0.003), which did not correlate with the human leukocyte
DR4 antigen.
Symptomatic (n 5 29) versus asymptomatic (n 5 44)
affected family members were characterized, as expected, by
all parameters indicative of left ventricular dysfunction and
dilation. However, no independent predictors were observed
at the multivariate analysis.
DISCUSSION
Identification of FDC. In this survey, the occurrence of an
inherited trait was detected in 39 out of 60 families of
patients with idiopathic DCM. The extensive analysis of
clinical and morphologic features of the 60 index patients
shows that there were no reliable clinical or morphologic
parameters able to predict the familial form. In this series,
only a more advanced age and a worse ventricular function
characterized the sporadic versus the familial cases, suggest-
ing different stages of the disease, rather than different
diseases. Likewise, no differences were found between
healthy relatives of sporadic and familial DCM patients.
The lack of differential features was probably due to the
etiologic heterogeneity of both groups.
These data, as well as the potential risk of misclassifica-
tion error (12.5% in this population) without a family
screening, stress the need for clinical examination of at least
the first-degree relatives of DCM patients, regardless of
their family history. The disease can be asymptomatic or
clinically not evident due to the reduced and age-related
penetrance. The family screening can detect initial cardiac
abnormalities in individuals of unknown status which may
represent early manifestations of the disease. These abnor-
malities, particularly frequent in the AD form (20% of the
patients’ relatives), have been shown to progress to overt
DCM in 27% of subjects (27).
Concerning the etiology of sporadic DCM, this could be
due to environmental factors such as viral infections, toxic
agents such as alcohol, autoimmunity (8) or multifactorial
mechanisms. However, a portion of the apparently sporadic
cases could also be caused by gene defects. The absence of
observed genetic transmission in these cases may be due to
Figure 2. Samples from the proband of a family with autosomal
dominant familial dilated cardiomyopathy showing myocarditis at
the histologic examination of the endomyocardial biopsy. (A)
Acute active myocarditis, with massive infiltration of lymphocytic,
monocytic and plasma cells, necrosis of adjacent myocardial fibers,
interstitial edema and disarrangement of the muscle bundles
(hematoxylin– eosin, 3120, reduced by 54%). (B) Healing
myocarditis, with interstitial edema and a focal inflammatory
infiltration with myocyte necrosis (hematoxylin– eosin, 3180,
reduced by 54%).
Figure 3. Echocardiographic features of autosomal dominant
hypertrophic–hypokinetic cardiomyopathy (AD-HDC). Apical
four-chamber view of individual III-3 of family AD-HDC1 (see
Fig. 1). Left frame: end-diastole; right frame: end-systole. The
left ventricle (LV) is only mildly dilated (end-diastolic volume 112
ml); a severe apical hypertrophy is present (arrows). The left
ventricle is diffusely hypokinetic, with moderate systolic dysfunc-
tion (ejection fraction 44%). LA 5 left atrium.
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de novo mutations such as those reported in hypertrophic
cardiomyopathy (28), or reduced penetrance in the carriers
masking their affected status or insufficient family data.
Clinical and molecular characterization of FDC. In this
study, the analysis of the phenotype, the genetic transmis-
sion and, when available, the molecular genetic data re-
vealed distinctive features among the different forms of
FDC, leading to a new classification of the familial forms in
our patient population. Our findings support the hypothesis
of genetic heterogeneity in FDC, which means that differ-
ent genes can cause the same syndrome.
In our population, the most common type of FDC was
the AD form with isolated myocardial involvement (56% of
our families). Autosomal dominant FDC was characterized
by mildly dilated forms in 42% of cases and by the presence
of cardiac autoantibodies in 72% of the affected individuals,
compared with 15% of sporadic cases and 3.5% of control
subjects (8). The identification of a high frequency of
cardiac autoantibodies in the forms with pure heart muscle
disease suggests an activation of an immune response, which
was independent from human leukocyte DR4 antigen.
There is no conclusive evidence that these antibodies are
directly pathogenetic (29), but they may represent reliable
markers of autoimmunity and may predict early disease
among relatives at risk of developing DCM (8).
Molecular genetic studies based on linkage analysis have
allowed the identification of four loci for AD FDC: on
chromosome 9 in three of our families (16), on chromosome
1q32 in another kindred (30), on chromosome 10q21-23 in
a family characterized by high penetrance and mitral pro-
lapse (31) and, very recently, on chromosome 2q31 in one
family (55).
The AR form of the disease was less frequent (16%). In
these families, both parents of the index patient were found
to be unaffected. Autosomal recessive FDC was character-
ized by a significantly younger age and a worse prognosis
compared with the dominant form, suggesting two distinct
etiologies.
Dilated cardiomyopathy with conduction defects was rare
in our series (2.6%). A peculiarity of this form was the onset
with severe conduction defect and only minor ventricular
dysfunction, subsequently followed by progressive heart
failure, as previously described (23). In this form, two
disease loci have been reported, one on chromosome 1p1-q1
(32) and the other on 3p22-p25 (33); the disease genes
mapping to these loci are still unknown.
Also rare in our study population were families with
unclassifiable FDC (7.7%). Two of these families showed a
peculiar phenotype characterized by apical hypertrophy and
AD transmission (Fig. 2). The third family was character-
ized by a complex phenotype, with hearing loss, retinitis
pigmentosa and apparently AR transmission. This pheno-
type, also observed in other patient populations (7), has been
reported in rare mitochondrial disorders (34,35), as well as
in AR disorders such as Alstrom syndrome (OMIM [On-
line Menolelian Inheritance in Man] #203800), Usher
syndrome (OMIM #276900) and Leber I syndrome
(OMIM #204000).
Most of the knowledge of the molecular basis of DCM
and of the genotype/phenotype correlation is due to the
identification of the gene causing XLDC (25,36), the
dystrophin gene. This gene encodes a large cytoskeletal
protein which plays a critical role in membrane stability,
force transduction and organization of the membrane in
skeletal and cardiac myocytes (37). X-linked dilated cardio-
myopathy was previously described in male teenagers, as a
rapidly progressive congestive heart failure, without clinical
signs of skeletal myopathy but with elevated serum
CK-MM (38). However, in our patients we observed an
older age, a less severe prognosis and, in one case, a normal
serum CK, indicating variable expressivity of this form of
the disease. These findings underline the need for a system-
atic and accurate skeletal muscle examination in FDC, even
in the absence of overt signs of myopathy. In XLDC, the
skeletal muscle biopsy is diagnostic and the definition of the
molecular defect is possible.
Molecular genetic analysis of the dystrophin gene dem-
onstrated three different mutations in our families. Two of
them were in the 59 end of the gene (17,25), whereas the
third was found in exon 48 (24), a region of the dystrophin
gene found to be mutated in Becker muscular dystrophy
with severe myocardial dysfunction (39). Interestingly, in
the first two families, expression studies showed that dys-
trophin was absent in the heart and partially replaced by the
compensatory production of other isoforms (brain and
Purkinje) in the skeletal muscles (17,26). Recently, muta-
Table 4. Uni- and Multivariate Analysis of the Difference Between Familial Dilated
Cardiomyopathy (FDC) With and Without Skeletal Muscle Involvement
“Pure” FDC
(63 Patients)
FDC With Myopathy
(11 Patients) p
Third heart sound (%) 27 64 0.020
Restrictive pattern (%) 6 40 0.054
LVEDP (mm Hg)* 12 (8–20) 21 (15–26) 0.022
Serum CK (U/liter)* 52 (37–89) 242 (83–423) 0.008
Organ-specific autoantibodies (%) 68 9 0.0196†
*Data are expressed as median (first and third quartile). †p value at multivariate analysis.
Restrictive pattern 5 on echocardiography. CK 5 creatine kinase; LVEDP 5 left ventricular end-diastolic pressure.
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tions of other regions of the gene have been implicated in
XLDC, such as a point mutation in exon 9 (40), a
duplication mutation involving exons 2–7 (41) and rear-
rangements of Alu-like sequences in intron 11 (42). These
regions are probably critical for the expression and function
of dystrophin in the heart.
The AD form with skeletal muscle involvement
(MDDC) is a novel entity, characterized by a highly variable
expressivity. A common feature of MDDC and XLDC was
a restrictive filling pattern. The gene causing MDDC is
unknown, but similar phenotypes were recently described in
families with limb girdle muscular dystrophy associated with
severe DCM. Two disease loci have been mapped, one to
chromosome 1 (43) and the other to chromosome 6 (44). By
analogy with dystrophin, other cytoskeletal proteins appear
to be potential candidates for causing DCM. A deficiency of
alpha sarcoglycan (adhalin) was observed in a patient with
muscle dystrophy and DCM (45). The absence of transcrip-
tion of metavinculin (the cardiac isoform of vinculin) was
reported in another FDC patient (46). Furthermore, delta-
sarcoglycan has been recently identified as the disease gene
of the Syrian hamster (BIO14.6) cardiomyopathy, and
mutations in another cytoskeletal gene, MLP, produce
cardiomyopathy in mice (47).
Recently, the analysis of candidate genes has allowed the
detection of missense mutations in the cardiac actin gene in
two small families with DCM (48). Cardiac actin has been
traditionally considered a sarcomeric gene. However, in the
two families described, the mutations occur in exons 5
(Arg312His) and 6 (Glu361Gly), leading to an altered inter-
action with the Z band and the intercalated disks. This
supports the hypothesis of a critical role of the cytoskeleton and
related structures for the integrity of myocardial function, and
the concept of a defect of force transmission in DCM, in
contrast to the defect of force generation due to mutations of
sarcomeric proteins in hypertrophic cardiomyopathy.
In this study, myocarditis, as defined by the Dallas criteria
(14), as well as mildly dilated cardiomyopathy and segmen-
tal wall motion abnormalities were detected in different
subgroups. The frequent finding of myocarditis is not
surprising, since histologic inflammation could represent
the acute stage of an autoimmune activation, particularly in
association with cardiac-specific autoantibodies (1), or con-
versely, an unspecific response to tissue injury mediated by
other noxae.
The molecular mechanisms causing the disease and the
genotype/phenotype correlations need to be fully defined.
Most of the genes causing FDC are still unknown, but it is
clear that their identification will have a considerable impact
in the prevention of DCM and treatment of DCM patients.
Besides the major disease genes, the variable penetrance and
expressivity of the disorder, and the different gender sus-
ceptibility, suggest the existence of modifier genes that
could affect the manifestation and severity of the disease.
For instance, genes of the renin–angiotensin system seem to
influence the severity of heart failure in ischemic and idiopathic
DCM (49), and are believed to influence the development of
hypertrophy in hypertrophic cardiomyopathy (50,51). More-
over, a complex genetic basis could account for the autoim-
mune subset of FDC, in keeping with the polygenic nature of
other autoimmune conditions, for example, type 1 insulin-
dependent diabetes mellitus (52). Finally, the increased
male/female ratio observed in forms with evidence of
autosomal transmission suggests the existence of suscepti-
bility factors associated with gender. The elucidation of the
mechanisms of these susceptibility or modifier genes could
provide other tools for the management of DCM.
Conclusions. The identification of a genetic background in
a large proportion of patients and the initial results of
clinical and molecular genetic studies showing genetic
heterogeneity represent important progress in the under-
standing of DCM and have relevant implications. The
management and the study of FDC require more sensitive
and specific diagnostic criteria; this need prompted the
European Collaboration on FDC to develop new guidelines
for family studies (53), which could represent the basis for a
common approach to the genetics of DCM, both in the
research and in the clinical context.
Several aspects still need to be fully elucidated, including
the natural history of FDC. In this study, minor cardiac
abnormalities were frequently seen in patients’ relatives
which could be early signs of disease (27). Furthermore,
previous studies reported a severe prognosis for FDC (54),
but our data suggest that different subtypes can have
different evolutions. Follow-up studies are needed to answer
these questions.
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